A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

Summary

This is a Phase 2, multicenter, open-label, noncomparative study to evaluate safety,efficacy and of single-agent EZN 2208 administered in patients with previously treated MBC. After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.

Timeline

Start

2009-11

Primary completion

2012-02

Completion

2012-12

Outcome

Outcome not reported

Stopped: “Program suspended and divested”

Drugs

Indications